
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is showing promising growth potential with a 20% increase in OviTex unit sales and a 18% Y/Y increase in revenue for the Q4/25 results. However, there may be potential for dilution in the future as the company continues to invest in its commercial infrastructure for future growth and may need to raise additional capital. The gross margin of 65.9% was also slightly lower than expected, potentially due to investment in new product launches.
Bears say
TELA Bio is a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions that prioritize patient anatomy preservation. While the company has best-in-class products and structural tailwinds, its ongoing execution risks from recent sales force restructuring keep the analyst cautious, resulting in a negative outlook. This was further reinforced by the lowered 2026 guidance and a highly concentrated product portfolio, which heavily relies on the timely approval and reimbursement from regulatory agencies.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares